# Phase 1.5 — Final Baseline Integrity Sign-Off

> **Document ID:** `SIGNOFF-PHASE1.5-FINAL-GATE`  
> **Repository:** `MULTIMODAL-FUSION-FOR-DETECTION-OF-COLORECTAL-CANCER-USING-CLINICAL-BERT-AND-PHIKONV2`  
> **Target Checkpoint:** [`models/fusion_model_v1_1.pth`](file:///d:/CRC%20Edge%20deployment/MULTIMODAL-FUSION-FOR-DETECTION-OF-COLORECTAL-CANCER-USING-CLINICAL-BERT-AND-PHIKONV2/models/fusion_model_v1_1.pth) (SHA-256: `e9a7bbcd...`, 5,250,561 float32 params)  
> **Holdout Manifest:** [`results/actual_validation_keys.json`](file:///d:/CRC%20Edge%20deployment/MULTIMODAL-FUSION-FOR-DETECTION-OF-COLORECTAL-CANCER-USING-CLINICAL-BERT-AND-PHIKONV2/results/actual_validation_keys.json) (66 isolated validation cases: 50 MSS, 16 MSI)  
> **Decision Threshold:** $\tau = 0.83$ (MSS: $P < 0.83$, MSI: $P \ge 0.83$)  
> **Inventory Artifact:** [`reports/mobile_deployment/phase1_5_validation_inventory.json`](file:///d:/CRC%20Edge%20deployment/MULTIMODAL-FUSION-FOR-DETECTION-OF-COLORECTAL-CANCER-USING-CLINICAL-BERT-AND-PHIKONV2/reports/mobile_deployment/phase1_5_validation_inventory.json)  
> **Final Recommendation:** **GO** (Pending Explicit Phase 2 Authorization)  

---

## 1. Executive Summary & Verification Scope

Phase 1.5 served as an independent audit and corrective-verification gate to ensure the mathematical reproducibility, numerical integrity, and procedural governance of the multimodal fusion baseline before authorizing ONNX model conversion.

All six sub-phase integrity audits have been completed with zero errors, zero asset mutations, and 100.0% regression pass:
1. **Sampling Reproducibility (Phase 1.5.1):** Identified order-dependence in legacy loop-level seeds; established an immutable, order-independent manifest ([`protocol1_patch_selection_manifest.json`](file:///d:/CRC%20Edge%20deployment/MULTIMODAL-FUSION-FOR-DETECTION-OF-COLORECTAL-CANCER-USING-CLINICAL-BERT-AND-PHIKONV2/reports/mobile_deployment/protocol1_patch_selection_manifest.json)) locking selected patch indices and SHA-256 tensor fingerprints for all 66 cases.
2. **Golden Reference Parity (Phase 1.5.2):** Fresh PyTorch execution matched the frozen golden reference ([`phase1_fp32_benchmark_data.json`](file:///d:/CRC%20Edge%20deployment/MULTIMODAL-FUSION-FOR-DETECTION-OF-COLORECTAL-CANCER-USING-CLINICAL-BERT-AND-PHIKONV2/reports/mobile_deployment/phase1_fp32_benchmark_data.json)) with **66/66 classification agreement (0 flips)** and maximum error bounded by $4.97 \times 10^{-7}$ (exclusively JSON 6-decimal rounding).
3. **Boundary Case Mapping (Phase 1.5.3):** Completed an exhaustive census of all cases within the boundary sensitivity zone $[0.78, 0.88]$; identified `CASE_36` as the ultra-critical case ($P=0.830106$, $+0.000106$ from threshold); proved that `CASE_20`'s protocol shift is driven by input sequence length, not numerical drift.
4. **Resource Profile Grounding (Phase 1.5.4):** Disambiguated decimal MB ($10^6$) from binary MiB ($2^{20}$); separated host multi-case RAM caching (peak RSS $665.33\text{ MB}$) from single-case mobile edge execution ($<25\text{ MB}$ activation RAM).
5. **Export-Readiness Inspection (Phase 1.5.5):** Isolated dead code at line 48 of `cross_attention_fusion.py` (`.numpy()` conversion); validated a non-invasive export wrapper strategy that avoids retraining or modifying model weights.
6. **Regression & Asset Protection (Phase 1.5.6):** Executed full regression suite including targeted manifest tests: **30 passed, 0 failed** in 11.81 seconds. All protected assets verified bit-intact.

---

## 2. Categorized Verification Synthesis

To uphold audit transparency, all technical statements are categorized into verified facts, estimates, assumptions, and unresolved risks:

### 2.1 Verified Facts (Empirically Proven)
* **Model Parameters:** Exactly **5,250,561** float32 parameters ($21,002,244\text{ bytes}$ buffer size; $21,007,347\text{ bytes}$ on-disk checkpoint).
* **Asset Immutability:** SHA-256 hashes of `fusion_model_v1_1.pth`, `patient_registry.json`, `actual_validation_keys.json`, and all 652 clean tensors match their initial audit states exactly.
* **Order-Dependence Proof:** Evaluating `CASE_20` sequentially after `CASE_19` under a single `torch.manual_seed(42)` produces only 24.4% patch overlap compared to evaluating `CASE_20` in isolation.
* **Manifest Invariance:** Evaluating all 66 cases in reverse order using the frozen manifest produces 0 fingerprint mismatches and identical model predictions.
* **Golden Parity:** Fresh PyTorch forward passes match the frozen reference database with 100.0% classification agreement across both Protocol 1 and Protocol 2.
* **Boundary Cases:** Exactly 3 cases fall in $[0.78, 0.88]$ under Protocol 1 (`CASE_35`, `CASE_36`, `CASE_59`); exactly 4 cases fall in $[0.78, 0.88]$ under Protocol 2 (`CASE_20`, `CASE_35`, `CASE_36`, `CASE_59`).
* **Test Suite:** `python -m pytest tests/ -v` passes 30/30 tests with exit code 0.

### 2.2 Calculated Estimates (Derived Analytically)
* **Precomputed Input Buffers:** Single patient text embedding requires $3.07\text{ KB}$ ($3.00\text{ KiB}$). Single patient vision embeddings require $1.57\text{ MB}$ ($1.50\text{ KiB}$) for median slide ($N=384$) and $4.10\text{ MB}$ ($3.91\text{ MiB}$) for capped sequence ($N=1000$).
* **Projected FP16 Parameter Footprint:** Halving parameter precision yields $10.50\text{ MB}$ ($10.01\text{ MiB}$) of model weights.
* **Peak Mobile Activation RAM:** Analytical cross-attention matrix $(1 \times 8 \times 1 \times 1000)$ plus layer normalizations and MLP buffers is estimated at $< 25\text{ MB}$ on mobile.

### 2.3 Documented Assumptions
* **Upstream Feature Cache Assumption (Mode 1):** The mobile application receives precomputed Phikon-v2 (`[1, N, 1024]`) and ClinicalBERT (`[1, 768]`) embeddings generated by an authorized pathology server or workstation pipeline. Foundation backbones (~1.5 GB) are strictly excluded from the mobile APK.
* **Deterministic Forward Execution:** PyTorch CPU execution using the same threading configuration and floating-point math libraries produces consistent results on the host development machine.

### 2.4 Unresolved Edge Risks & Mitigation Strategies
* **Risk 1: `CASE_36` Ultra-Near-Boundary Flip Risk:**
  - *Risk:* `CASE_36` sits at $P = 0.830106$ (+0.000106 above threshold). Standard FP32 matrix multiplication accumulation reassociation across ONNX Runtime CPU could cause a tiny negative drift ($\Delta P \approx -0.00015$) flipping it from TP to FN.
  - *Mitigation:* In Phase 2, `CASE_36` will be isolated for bit-level operator tracking. A flip will not be treated as a catastrophic regression if logit and probability differences remain within the established tolerance ($\le 10^{-4}$).
* **Risk 2: FP16 Quantization Divergence:**
  - *Risk:* Machine epsilon for float16 is $\epsilon \approx 9.77 \times 10^{-4}$ ($0.001$), which exceeds the distance to threshold for `CASE_36`.
  - *Mitigation:* FP32 acceptance limits will **not** be assumed for FP16. Phase 3 will establish a dedicated FP16 acceptance contract with fallback layer options (e.g., retaining attention softmax and classifier head in FP32).
* **Risk 3: Unverified Mobile Performance:**
  - *Risk:* Host CPU latency ($139.80\text{ ms}$) and memory ($665.33\text{ MB}$) cannot predict Android on-device performance.
  - *Mitigation:* Projections are labeled as estimates; real physical device profiling will be conducted exclusively in Phase 4.

---

## 3. Working-Tree & Asset Verification Log

| Asset File | Expected SHA-256 | Verified SHA-256 | Verification Status |
| :--- | :--- | :--- | :---: |
| `models/fusion_model_v1_1.pth` | `e9a7bbcdbe1713a0ed14b6ecd511ac65d046a52e2f03c69443f5bd3dcf12d453` | `e9a7bbcdbe1713a0ed14b6ecd511ac65d046a52e2f03c69443f5bd3dcf12d453` | **INTACT** |
| `data/patient_registry.json` | `7d1c92c51741e080787607733a8b34cb07252c804f527cd567937345a5b22ce2` | `7d1c92c51741e080787607733a8b34cb07252c804f527cd567937345a5b22ce2` | **INTACT** |
| `results/actual_validation_keys.json` | `61d7f8d98388efbe9fc5e000d695b2f41022720a14a8308a6317bc9441930aa9` | `61d7f8d98388efbe9fc5e000d695b2f41022720a14a8308a6317bc9441930aa9` | **INTACT** |
| `data/clean_tensors/` (652 files) | `3a57ef2f7424e010d27f327a701c8d3042a82c3cc60bbb029313cef1428312a1` | `3a57ef2f7424e010d27f327a701c8d3042a82c3cc60bbb029313cef1428312a1` | **INTACT** |

* **Active Git Branch:** `edge-deployment`
* **Current Commit:** `189b6638c31d80344ecc8c45133c7058c3e47fa1`
* **Intentionally Preserved Files:** User changes in `src/ui/app.py` and pre-existing PNG plots in `results/` were untouched throughout Phase 1.5.

---

## 4. Phase 1.5 Deliverables Summary

| Deliverable File | Description | Status |
| :--- | :--- | :---: |
| [`reports/mobile_deployment/phase1_5_1_sampling_reproducibility_audit.md`](file:///d:/CRC%20Edge%20deployment/MULTIMODAL-FUSION-FOR-DETECTION-OF-COLORECTAL-CANCER-USING-CLINICAL-BERT-AND-PHIKONV2/reports/mobile_deployment/phase1_5_1_sampling_reproducibility_audit.md) | Order-dependence proof & manifest governance | **COMPLETE** |
| [`reports/mobile_deployment/phase1_5_2_golden_reference_audit.md`](file:///d:/CRC%20Edge%20deployment/MULTIMODAL-FUSION-FOR-DETECTION-OF-COLORECTAL-CANCER-USING-CLINICAL-BERT-AND-PHIKONV2/reports/mobile_deployment/phase1_5_2_golden_reference_audit.md) | Golden dataset parity & FP32 tolerance contract | **COMPLETE** |
| [`reports/mobile_deployment/phase1_5_3_boundary_case_audit.md`](file:///d:/CRC%20Edge%20deployment/MULTIMODAL-FUSION-FOR-DETECTION-OF-COLORECTAL-CANCER-USING-CLINICAL-BERT-AND-PHIKONV2/reports/mobile_deployment/phase1_5_3_boundary_case_audit.md) | Boundary sensitivity census & case vulnerability mapping | **COMPLETE** |
| [`reports/mobile_deployment/phase1_5_4_resource_claims_audit.md`](file:///d:/CRC%20Edge%20deployment/MULTIMODAL-FUSION-FOR-DETECTION-OF-COLORECTAL-CANCER-USING-CLINICAL-BERT-AND-PHIKONV2/reports/mobile_deployment/phase1_5_4_resource_claims_audit.md) | Disambiguation of units & measured vs. estimated resources | **COMPLETE** |
| [`reports/mobile_deployment/protocol1_patch_selection_manifest.json`](file:///d:/CRC%20Edge%20deployment/MULTIMODAL-FUSION-FOR-DETECTION-OF-COLORECTAL-CANCER-USING-CLINICAL-BERT-AND-PHIKONV2/reports/mobile_deployment/protocol1_patch_selection_manifest.json) | Immutable patch selection manifest & tensor fingerprints | **COMPLETE** |
| [`reports/mobile_deployment/phase1_5_validation_inventory.json`](file:///d:/CRC%20Edge%20deployment/MULTIMODAL-FUSION-FOR-DETECTION-OF-COLORECTAL-CANCER-USING-CLINICAL-BERT-AND-PHIKONV2/reports/mobile_deployment/phase1_5_validation_inventory.json) | Machine-readable validation inventory (schema 1.5.0) | **COMPLETE** |
| [`tests/test_sampling_manifest.py`](file:///d:/CRC%20Edge%20deployment/MULTIMODAL-FUSION-FOR-DETECTION-OF-COLORECTAL-CANCER-USING-CLINICAL-BERT-AND-PHIKONV2/tests/test_sampling_manifest.py) | Automated test suite verifying manifest reproducibility | **COMPLETE** |

---

## 5. Final Decision Gate Recommendation

### Recommendation: **GO**

**Justification:**  
1. All mathematical, data-integrity, and reproducibility gates have been satisfied.
2. The patch-selection manifest permanently resolves order-dependence and isolated-execution drift.
3. The frozen reference outputs exhibit exact sub-microsecond consistency with fresh PyTorch evaluations across all 66 cases.
4. Proposed FP32 tolerance limits ($10^{-4}$ logit/prob error, $10^{-5}$ MAE) are technically justified and ready for enforcement.
5. The export blocker at line 48 is fully understood and solvable via a non-invasive wrapper.
6. The full regression test suite (30/30 passed) confirms zero breakage of existing project functionality.

**Mandatory Next Step:**  
In accordance with sequential governance rules, execution stops here. Model conversion, package installations, and Android work will begin only upon receiving your explicit authorization for **Phase 2 (ONNX Model Conversion & Parity Verification)**.
